Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: a Pivotal Randomized Double Masked Placebo Controlled Study

Trial Profile

Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: a Pivotal Randomized Double Masked Placebo Controlled Study

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 15 Jun 2017

At a glance

  • Drugs Biotin (Primary)
  • Indications Multiple sclerosis; Optic neuritis
  • Focus Registrational; Therapeutic Use
  • Acronyms MS-ON
  • Sponsors MedDay Pharmaceuticals
  • Most Recent Events

    • 23 Mar 2017 Planned End Date changed from 1 Jan 2016 to 1 Jan 2018.
    • 21 Apr 2016 According to a MedDay media release, full results of this trial were presented at the American Academy of Neurology Annual Meeting 2016.
    • 21 Apr 2016 Results published in a MedDay media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top